Researchers track 300 patients with Pre-MDS conditions to uncover progression patterns
NCT ID NCT04428489
First seen Jan 04, 2026 · Last updated Jun 21, 2026 · Updated 27 times
Summary
This study follows 300 people who have persistent low blood cell counts (cytopenia) but do not yet have myelodysplastic syndromes (MDS). The goal is to see how often these pre-MDS conditions (called ICUS and CCUS) turn into MDS over time. Participants receive standard supportive care but no extra treatment. The results could help doctors better predict and monitor disease progression in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this study could help doctors better predict which patients with early blood abnormalities will develop MDS, leading to earlier monitoring or intervention.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly help participants. Results may not apply to all populations, and the follow-up period may be too short to capture all progression events.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.